AI-Guided Peptide
Discovery Platform

Neomera Platform: AI-Guided Selectivity

AI Platform Trained on Comprehensive Positive + Negative Selection Data Solving Target Specificity

AI Drug Discovery Challange

  • Trained solely on positive binding data from public database
  • 90% of drugs failed due to selectivity issues, each failutre cost 10+ years and $2.5 Billion

Neomera's Solution

  • Proprietary negative selection datasets teach AI what NOT to bind
  • Screens Mmultiple related targets simultaneously in a single screening round
  • AI algorithm maps amino acid patterns to binding function, revealing what makes drugs selective for specific targets
  • Lightweight AI runs without expensive GPU infrastructure